BIOMAT Database Logo BIOMAT Database Logo

Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase: a new class of antiviral agents. 1995

N Moss, and P Beaulieu, and J S Duceppe, and J M Ferland, and J Gauthier, and E Ghiro, and S Goulet, and L Grenier, and M Llinas-Brunet, and R Plante
Bio-Méga/Boehringer Ingelheim Research Inc., Laval, Québec, Canada.

We have been investigating a new class of antiviral compounds effective against herpes simplex virus (HSV) in vitro and in vivo. Antiviral activity results from inhibition of HSV ribonucleotide reductase (RR). The inhibitors are designed as mimics of the RR small subunit C-terminus, a region essential for RR subunit association and consequently enzymatic activity. Inhibition results from specific binding of the inhibitor to the HSV RR large subunit thereby preventing subunit association. This report details the structure--activity studies that lead to the indentification of BILD 1263, a potent inhibitor of HSV RR subunit association (IC50, 0.2 nM) that also inhibits the replication of HSV types 1 and 2 in cell culture (EC50, 3 and 4 microM) and reduces the severity of HSV-1-induced keratitis in a murine ocular model. The discovery of inhibitors with in vitro antiviral results from a combination of improving inhibitor potency in a RR binding assay and modifying inhibitor physicochemical properties. The importance and possible role of the new structural modifications introduced into this inhibitor series is discussed.

UI MeSH Term Description Entries
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012264 Ribonucleotide Reductases Ribonucleotide Reductase,Reductase, Ribonucleotide,Reductases, Ribonucleotide
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D018258 Herpesvirus 2, Human A species of SIMPLEXVIRUS associated with genital infections (HERPES GENITALIS). It is transmitted by sexual intercourse and close personal contact. HSV-2,Herpes Simplex Virus 2,Human Herpesvirus 2,HHV-2,Herpes Simplex Virus Type 2,Herpesvirus 2 (alpha), Human

Related Publications

N Moss, and P Beaulieu, and J S Duceppe, and J M Ferland, and J Gauthier, and E Ghiro, and S Goulet, and L Grenier, and M Llinas-Brunet, and R Plante
Resistance of herpes simplex virus type 1 to peptidomimetic ribonucleotide reductase inhibitors: selection and characterization of mutant isolates.
February 1996, Journal of virology,
N Moss, and P Beaulieu, and J S Duceppe, and J M Ferland, and J Gauthier, and E Ghiro, and S Goulet, and L Grenier, and M Llinas-Brunet, and R Plante
Inhibition of herpes simplex virus ribonucleotide reductase by synthetic nonapeptides: a potential antiviral therapy.
January 1992, Advances in experimental medicine and biology,
N Moss, and P Beaulieu, and J S Duceppe, and J M Ferland, and J Gauthier, and E Ghiro, and S Goulet, and L Grenier, and M Llinas-Brunet, and R Plante
Ribonucleotide reductase inhibitors as anti-herpes agents.
September 2006, Antiviral research,
N Moss, and P Beaulieu, and J S Duceppe, and J M Ferland, and J Gauthier, and E Ghiro, and S Goulet, and L Grenier, and M Llinas-Brunet, and R Plante
Disruption of herpes simplex virus ribonucleotide reductase quaternary structure by peptide inhibitors as a novel approach to antiviral therapy.
October 1995, Journal of chemotherapy (Florence, Italy),
N Moss, and P Beaulieu, and J S Duceppe, and J M Ferland, and J Gauthier, and E Ghiro, and S Goulet, and L Grenier, and M Llinas-Brunet, and R Plante
Ribonucleotide reductase inhibitors as anticancer and antiviral agents.
January 1987, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques,
N Moss, and P Beaulieu, and J S Duceppe, and J M Ferland, and J Gauthier, and E Ghiro, and S Goulet, and L Grenier, and M Llinas-Brunet, and R Plante
Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease.
May 1996, Antimicrobial agents and chemotherapy,
N Moss, and P Beaulieu, and J S Duceppe, and J M Ferland, and J Gauthier, and E Ghiro, and S Goulet, and L Grenier, and M Llinas-Brunet, and R Plante
Antiviral agents for herpes simplex virus.
January 2013, Advances in pharmacology (San Diego, Calif.),
N Moss, and P Beaulieu, and J S Duceppe, and J M Ferland, and J Gauthier, and E Ghiro, and S Goulet, and L Grenier, and M Llinas-Brunet, and R Plante
Susceptibility of a herpes simplex virus ribonucleotide reductase null mutant to deoxyribonucleosides and antiviral nucleoside analogs.
January 1991, Microbiology and immunology,
N Moss, and P Beaulieu, and J S Duceppe, and J M Ferland, and J Gauthier, and E Ghiro, and S Goulet, and L Grenier, and M Llinas-Brunet, and R Plante
Herpes simplex type 1 ribonucleotide reductase. Mechanism studies with inhibitors.
July 1985, The Journal of biological chemistry,
N Moss, and P Beaulieu, and J S Duceppe, and J M Ferland, and J Gauthier, and E Ghiro, and S Goulet, and L Grenier, and M Llinas-Brunet, and R Plante
Ribonucleotide reductase of herpes simplex virus type 2 resembles that of herpes simplex virus type 1.
December 1984, Journal of virology,
Copied contents to your clipboard!